title: [Adjuvant and salvage radiotherapy after radical prostatectomy].
abstract: After radical prostatectomy is important to identify patients who have a high risk of microscopic residual disease without micrometastatic disease. Adjuvant RT, in retrospective studies, reduce the risk of recurrence and is more efficacious than salvage RT and can improve PSA relapse-free survival and should have an impact on long-term overall survival. The benefit of androgen suppression could be due to a synergistic interaction and may possibly eliminate occult systemic disease. Appropriate selection to identify subgroups of patients who may benefit from salvage RT, even for those patients at the highest risk; and whether some form of hormone ablation should accompany. To predict the biochemical failure and the risk of metastatic disease after salvage RT. We analyze the references to select an appropriate therapy. Improved outcomes will need to be tested in randomized trials.
authors.affiliation: Servicio de Oncología Radioterápica, Fundación Instituto Valenciano de Oncología, Valencia. jmengual@fivo.org
authors.forename: J L
authors.initials: JL
authors.lastname: Mengual Cloquell
authors.forename: P P
authors.initials: PP
authors.lastname: Escolar Pérez
authors.forename: M
authors.initials: M
authors.lastname: Casaña Giner
authors.forename: M L
authors.initials: ML
authors.lastname: Chust Vicente
authors.forename: J L
authors.initials: JL
authors.lastname: Guinot Rodríguez
authors.forename: L
authors.initials: L
authors.lastname: Arribas Alpuente
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D016879:Salvage Therapy
chemical_list: D018931:Antineoplastic Agents, Hormonal